Behçet Disease: Definition and Management
Definition
Behçet disease is a chronic, relapsing-remitting multisystem inflammatory disorder characterized by systemic vasculitis affecting vessels of all sizes, with hallmark clinical features of recurrent oral and genital ulcers, skin lesions, and uveitis 1. The disease predominantly affects populations along the historical Silk Road (Mediterranean, Middle East, East Asia), with prevalence estimated at 10.3 per 100,000 population 2. Pathologically, it involves neutrophil infiltration and endothelial damage, with strong genetic association to HLA-B*51 allele 3.
Management Strategy: Risk-Stratified Approach
Overarching Treatment Principles
The fundamental goal is to rapidly suppress inflammation and prevent irreversible organ damage through early aggressive treatment 1. Treatment intensity must match organ-specific risk:
- High-risk manifestations (ocular, vascular, neurological, gastrointestinal): Require immediate aggressive immunosuppression to prevent permanent damage or death
- Low-risk manifestations (mucocutaneous, articular): Stepwise approach balancing symptom control against treatment toxicity
- Young males with early disease onset: More aggressive treatment warranted due to worse prognosis 1
Organ-Specific Management Algorithm
1. Mucocutaneous Involvement (Oral/Genital Ulcers, Skin Lesions)
First-line: Colchicine - particularly effective for erythema nodosum and genital ulcers 1, 4
- Add topical corticosteroids for symptomatic relief of active ulcers 1
- Treat papulopustular/acne-like lesions as acne vulgaris (topical or systemic) 1
Refractory cases - escalate to:
Critical caveat: Chronic scarring ulceration requires vigorous treatment to prevent oropharyngeal narrowing and obliterative genital scarring 1.
2. Ocular Involvement (Uveitis)
Any posterior segment involvement requires immediate systemic immunosuppression - delays cause irreversible vision loss 1, 5.
Maintenance therapy (choose one):
- Azathioprine (Level IB evidence) 1
- Cyclosporine-A (Level IB evidence) 1
- Interferon-alpha (Level IIA evidence) 1
- Monoclonal anti-TNF antibodies (Level IIA evidence) 1
Acute sight-threatening exacerbations:
- High-dose glucocorticoids PLUS
- Infliximab OR interferon-alpha 1
- Consider intravitreal glucocorticoid injection for unilateral disease as adjunct 1
Critical rule: Never use systemic glucocorticoids as monotherapy - always combine with azathioprine or other immunosuppressives 1.
3. Major Vascular Involvement
Early monoclonal anti-TNF antibodies are encouraged for life-threatening vascular manifestations 4, 6. The intensive upfront approach is critical because delays in inflammation control correlate with irreversible damage 5.
Treatment components:
- Glucocorticoids for acute inflammation
- Immunosuppressives (cyclophosphamide has evolving role) 6
- Monoclonal anti-TNF antibodies (infliximab preferred based on strongest data) 6
4. Neurological Involvement
Requires aggressive immunosuppression immediately - neurological damage is associated with poor prognosis 1.
Approach:
- High-dose glucocorticoids
- Immunosuppressives
- Early monoclonal anti-TNF antibodies for severe/refractory cases 4
5. Gastrointestinal Involvement
Associated with poor prognosis - treat aggressively 1.
Strategy:
- Glucocorticoids for acute inflammation
- Immunosuppressives
- TNF-alpha inhibitors for refractory disease 1
6. Joint Involvement
Stepwise approach similar to mucocutaneous disease:
First-line: Colchicine 4
Refractory cases: Escalate to apremilast or immunosuppressives including TNF-alpha inhibitors 4
Biologic Therapy Selection
Monoclonal anti-TNF antibodies (infliximab, adalimumab) have the strongest disease-specific evidence across all manifestations 5, 6. Infliximab and adalimumab show comparable efficacy, though comparative data remain limited 6.
Alternative biologics for refractory cases:
Important limitation: Treatment response varies across organ systems - benefit in one domain cannot be assumed to translate to others, requiring organ-specific treatment planning 5.
Key Clinical Pitfalls
Never delay aggressive treatment for major organ involvement - irreversible damage occurs rapidly 1, 5
Never use glucocorticoids alone for ocular disease - must combine with immunosuppressives 1
Recognize that disease manifestations ameliorate over time - treatment can be tapered or stopped during disease course 1, 4
Young males with early onset require heightened vigilance - more severe disease course 1
Multidisciplinary collaboration is essential - ophthalmology for eye disease, vascular surgery for leg ulcers, dermatology for complex skin manifestations 1, 4
Treatment Tapering
As disease activity decreases over time, treatment may be tapered and potentially discontinued 1. This decision requires careful monitoring for relapse, particularly in patients with history of major organ involvement.